Navigation Links
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
Date:4/29/2008

s for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the preclinical data and plans and potential efficacy of R788. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "may," "can," "support," "indicate," "potential," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, potential problems that may arise in the clinical testing and approval process and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-K for the year ended December 31, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: rrodriguez@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
3. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
4. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
9. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
10. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
11. Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  Sage Analytics ( www.sageanalytics.com ), the ... the testing of marijuana potency and moisture content, ... Profiler, the industry,s first product suite capable of ... portable unit. Designed from the ground ... cannabis industry, the Luminary™ Profiler utilizes specially purposed ...
(Date:12/19/2014)... -- Capnia, Inc. (NASDAQ: CAPN ), ... on its proprietary Sensalyze™ Technology Platform for precision ... for the third quarter and nine months ended ... of our initial public offering (IPO), we are ... CoSense® commercial launch," said Anish Bhatnagar, M.D., Chief ...
(Date:12/19/2014)... 2014 Baptist Health Lexington is the first facility ... full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status from ... fibrillation is the most common cardiac arrhythmia and has become ... lead to stroke and possible death. More than 5 million ... atrial fibrillation and the numbers are rapidly increasing as the ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... sexual health company, TivaMed, today announced it has changed its ... of its Viveve system to OB/GYNs in select U.S. markets. ... essence of our company focus on women,s sexual health," said ... the sole purpose of helping women restore their sense of ...
... , VIRGINIA BEACH, Va., Nov. 9 LifeNet ... launch of Vertigraft Cervical Bio-Implant (VG2C) with Preservon® ... preservation solution that allows allograft bio-implants to be ... temperature. This eliminates the need to freeze or ...
Cached Medicine Technology:Women's Sexual Health Company Changes Name in Preparation for Market Entry 2LifeNet Health Announces First Bio-Implant with New Preservation Technology 2
(Date:12/22/2014)... 2014 Physicians in China are most ... treatment of non-Hodgkin’s lymphoma (NHL), according to a new ... healthcare consulting firm. MabThera is the only biologic available ... common form of NHL. , According to Kantar Health’s ... incidence of NHL in China has been growing and ...
(Date:12/22/2014)... Nevada (PRWEB) December 22, 2014 Only ... several southern and mid-western cities to have a battery ... TalkLocal ( http://www.talklocal.com ) is launching in ... local economy. , “A strong manufacturing sector is ... TalkLocal founder Gurpreet Singh explained, “and TalkLocal works with ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Pasadena ... offering consultations for sleep apnea. Drowsy drivers are 15 ... drivers who are well-rested, and some experts believe that ... roads as intoxicated drivers. Unfortunately, millions of Americans may ... American Academy of Sleep Medicine, about 18 million Americans ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
... cause permanent damage, researchers say , , FRIDAY, Feb. 8 ... and cause problems such as disturbed sleep, depression, anxiety ... , Researchers at Northwestern University,s Feinberg School of Medicine ... in people with chronic low back pain while they ...
... during the transition from high school through the first ... psychological implications, according to a report out of the ... good news is that during the first year of ... majority (78 percent) of the 870 incoming freshmen women ...
... NHS Choices ( http://www.nhs.uk ), the,online ,front ... news service to,help people make sense of the ... Behind the headlines, on NHS Choices,( http://www.nhs.uk/News/Pages/NewsIndex.aspx ), ... the news. The service explains the,facts behind newspaper ...
... - code situations in hospital parlance - easily expose common ... for children and also set up powerful incentives to ... a study from the Johns Hopkins Childrens Center. , ... and published in the January issue of Pediatrics, found sometimes ...
... 8 Symmetry Medical Inc.,(NYSE: SMA ), a ... industry and other medical markets, today announced it,will provide ... on,February 14, 2008 before the opening of the U.S. ... at 8:00 a.m. ET on,February 14, 2008., A ...
... Annual Event Raises Funds and Awareness for Chronic ... Feb. 8 The following release was,issued today ... Capital,Area:, WHO: Casino Night attracts a diverse ... medical and philanthropic communities in the Greater,Washington, DC ...
Cached Medicine News:Health News:Chronic Pain Harms Brain's Wiring 2Health News:A dangerous transition: High school to the first year of college 2Health News:A dangerous transition: High school to the first year of college 3Health News:A dangerous transition: High school to the first year of college 4Health News:Mock CPR 'codes' expose weaknesses in hospital emergency response for children 2Health News:Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: